![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The linDNA-LNP vaccine, designed and manufactured, will be used in upcoming in vivo animal studies to assess the performance of linDNA-LNP vaccines and will inform the final design of the company’s lead veterinary asset, a linDNA-LNP canine lymphoma vaccine candidate.
Lead Product(s): LinearDNA SARS-CoV-2 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: EvviVax
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2022